CodeBreak 101
22 Nov 2021
CodeBreak 101
NCT04185883
A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I, Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Advanced |
Anticipated Start Date | 2019-12-17 |
Anticipated End Date | 2024-01-12 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Dr Timothy Price |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs